Support for late effects after donor stem cell transplant
Part of Blood & lymphatic clinical trials.
This trial offers support and guidance for people who have had a donor stem cell transplant and are managing long-term side effects. It aims to help you better handle late effects and improve your quality of life after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have had a stem cell transplant from a donor (allogeneic).
- Your cancer has not come back, and you are not being treated for a new cancer.
- You have access to email and the internet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well patients do after receiving a stem cell transplant from a donor (called an allogeneic transplant). It aims to better understand the long-term outcomes and help improve care for future patients.
This study looks at the long-term health effects of hematopoietic (blood-forming) stem cell transplants. It may help doctors better understand and manage late side effects for children and teens after transplant.
This study looks at whether a rehabilitation and exercise program can help people recover after an allogeneic stem cell transplant. It aims to improve your recovery and quality of life after the transplant.
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
This trial uses donor immune cells (lymphocytes) after a stem cell transplant to help fight any remaining cancer in people with high-risk blood cancers. It aims to lower the chance of the cancer coming back.
This trial studies a special donor stem cell transplant where the donor’s immune cells are reduced, aiming to lower harmful immune attacks after transplant. It may help children and young adults with certain high-risk blood cancers or rare bone marrow disorders.
Hear when a new Hematological Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.